Male Health

FDA approves IND application of Accutar for a prostate cancer treatment trial The US Food and Drug Administration (FDA) has granted Accutar Biotechnology’s Investigational New Drug (IND) application for Phase I clinical trial of AC0176 for treating metastatic castration-resistant prostate cancer (mCRPC). An investigational orally bioavailable, chimeric degrader molecule, AC0176, is designed to aim and degrade androgen receptor (AR) for prostate cancer treatment. AR is a hormone-regulated transcription factor, which plays a prominent role in the initiation and progression of prostate cancer. Accutar stated that AC0176 showed selective and robust degradation o...